Comparison of xylazine and dexmedetomidine as a premedicant for general anaesthesia in dogs

ROHIN SHARMA; ADARSH KUMAR; AMIT KUMAR; S K SHARMA; ARVIND SHARMA; NEELIMA TEWARI

doi:10.56093/ijans.v84i1.37288

Authors

ROHIN SHARMA CSK Himachal Pradesh Agricultural University, Palampur, Himachal Pradesh 176 062 India
ADARSH KUMAR CSK Himachal Pradesh Agricultural University, Palampur, Himachal Pradesh 176 062 India
AMIT KUMAR CSK Himachal Pradesh Agricultural University, Palampur, Himachal Pradesh 176 062 India
S K SHARMA CSK Himachal Pradesh Agricultural University, Palampur, Himachal Pradesh 176 062 India
ARVIND SHARMA CSK Himachal Pradesh Agricultural University, Palampur, Himachal Pradesh 176 062 India
NEELIMA TEWARI CSK Himachal Pradesh Agricultural University, Palampur, Himachal Pradesh 176 062 India

https://doi.org/10.56093/ijans.v84i1.37288

Keywords:

Dexmedetomidine, Dogs, Haemato-biochemical, Induction, Recovery, Xylazine

Abstract

Adult dogs (32) of either sex, divided into 2 groups were used for evaluation of anesthetic efficacy of xylazine (1mg/ kg IV) and dexmedetomidine (375µg/m2 IV) in atropine-butorphanol premedicated and ketamine (till effect IV) induced dogs which were further maintained on halothane. Clinical parameters and reflexes (induction dose, intubation time, jaw relaxation, pedal, palpebral and photo-pupillary) were measured at baseline (pre-operative), just after induction and at 5, 15, 30 and 45 min after the start of halothane. Similarly, haemato-biochemical parameters were measured at baseline (pre-operative), intraoperative and postoperative phase along with recovery parameters. On comparative basis, induction dose of ketamine was 3.7 and 2.9 mg/kg body weight and intubation time 81.29±6.22 and 45.87±3.95 sec in group BXK and BDK groups respectively. Uniform and pronounced muscle relaxation along with excellent sedation was found in both the groups. All haemato-biochemical parameters remained within normal range except hyperglycaemia was observed during late phase in both groups. Mean vaporizer concentration of halothane was 2 and 1.26% in BXK and BDK group respectively. Following discontinuation of the halothane, all the recovery times of BDK group took significantly lesser time than group BXK along with superior quality of recovery.

Downloads

Download data is not yet available.

References

Ahmad R A, Amarpal P Kinjavdekar, Aithal H P, Pawde A M and Kumar D. 2013. Potential use of dexmedetomidine for different levels of sedation, analgesia and anaesthesia in dogs. Veterinarni Medicina 58(2): 87–95.

Ahmad R A, Amarpal P Kinjavdekar, Aithal H P, Pawde A M and Kumar D. 2011. Effects of Midazolam-Fentanyl on Sedation and Analgesia produced by Intramuscular dexmedetomidine in dogs. Asian Journal of Animal Sciences 5(5): 302–16.

Amend J F, Klavano P A and Stone E C. 1972. Premedication with xylazine to eliminate muscular hypertonicity in cats during ketamine anesthesia. Veterinary Medical Small Animal Clinics 67(12): 1305.

Burton S A, Lemke K A, Ihle S L and Mackenzie A L. 1997. Effects of medetomidine on serum insulin and plasma glucose concentrations in clinically normal dogs. American Journal of Veterinary Research 58(12): 1440–42.

Dexdomitor. 2006. Freedom of Information Summary. NADA 141–267. www.fda.gov/cvm/FOI/141-267o120106.pdf [27th November, 2011]

Fleknell P A. 2009. Laboratory Animal Anaesthesia. 3rd edn. Academic Press, London.

Gertler R, Brown C H, Mitchell D and Silvius E N. 2001. Dexmedetomidine: a novel sedative-analgesic agent. Baylor University Medical Center Proceedings 14(1): 13–21

Gracia V R, Toutain P L, Alvinerie M and Ruckebusch Y. 1981. The pharmacokinetics of xylazine hydrochloride: An interspecies study. Journal of Veterinary Pharmacology and Therapeutics 4(2): 87–92.

Hikasa Y, Yamashita M, Takase K and Ogsawa S. 1998. Prolonged sevoflurane, isoflurane and halothane anesthesia in oxygen using rebreathing or nonrebreathing system in cats. Journal of Veterinary Medicine 45(9): 559–75.

Hsu W H. 1981. Xylazine induced depression and its antagonism by alpha adrenergic blocking agents. Journal of Pharmacology and Experimental Therapeutics 218(1): 188–92.

Kending J J, Savola M K, Woodley S J and Maze M. 1991. Alpha 2-adrenoceptors inhibit a nociceptive response in neonatal rat spinal cord. European Journal of Pharmacology 192(2): 293– 300.

Komnenou A, Karayannopoulou M, Polizopoulou Z S, Constantinidis T C and Dessiris A. 2005. Correlation of serum alkaline phosphatase activity with the healing process of long bone fracture in dogs. Veterinary Clinical Pathology 34(1): 35– 38.

Ko J C H, McGrath C J and Nicklin C F. 1997. Answers to your questions about medetomidine and atipamezole. Veterinary Medicine May. Pp. 415–25.

Kuusela E, Raekallio M, Antilla M, Flack I, Mosla S and Vainio O. 2000. Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. Journal of Veterinary Pharmacology and Therapeutics 23(1): 15–20.

Kuusela E, Raekallio M, Vaisanen M, Mykkanen K, Ropponen H and Vainio O. 2001. Comparison of medetomidine and dexmedetomidine as premedicants in dogs undergoing propofol- isoflurane anesthesia. Ameican Journal of Veterinary Research 62(7): 1073–80.

Lemke K A. 2004. Perioperative use of selective alpha–2 agonists and antagonists in small animals. Canadian Veterinary Journal 45(6): 475–80.

Marjorie E G. 2001. Tranquilizers, a2-adrenergic agonists, and related agents. Veterinary Pharmacology and Therapeutics. (Ed.) Adams H R. 8th edn. pp. 268–98. Iowa State University Press, Ames, Iowa.

Naghibi K H, Yaraghi A and Adibi P. 2002. Haemoglobin and haematocrit changes during uncomplicated anesthesia. General Anaesthesia and Local Anaesthesia 7(4): 9.

Santosh K M, Amarpal, Ahmad R A, Kinjavdekar P, Aithal H P and Pawde A M. 2012. Effect of increased dose of dexmedetomidine vis-a-vis addition of fentanyl on clinical and cardiorespiratory actions of dexmedetomidine-midazolam- ketamine anesthesia in dogs. Asian Journal of Animal Sciences 6(2): 51–64.

Schwartz D D and Clarke T P. 1998. Affinity of detomidine, medetomidine and xylazine for alpha-2 adrenergic receptor subtypes. Journal of Veterinary Pharmacolgy and Therapeutics 21: 107–111.

Selmi A L, Mendes G M, Lins B T and Figuueiredo J P. 2003. Evaluation of the sedative and cardiorespiratory effects of dexmedetomidine, dexmedetomidine-butorphanol, an dexmedetomidine-ketamine in cats. Journal of the American Veterinary Medical Association 222(1): 37–41.

Standhoy J W, Ott C E, Schneider E G, Willis L R, Beck N P, Davis B B and Knox F G. 1974. Effects of prostaglandins E1 and E2 on renal sodium reabsorption and Starling forces. American Journal of Physiology 226: 1015–21.

Virtanen R, Savola J M, Saano V and Nyman L. 1988. Characterization of the selectivity, specificity and potency of medetomidine as an alpha-2 adrenoceptor agonist. European Journal of Pharmacology 150: 9–14.

Ylitalo P, Saarnivaara L and Ahtee L. 1976. The effect of ketamine anaesthesia on the control of monoamide and their metabolites in cat brain. Acta Anaesthesiology Scandinavica 20(3): 216–20.